Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms.

At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return is down 45.27%. This points to fading momentum despite the recent shareholder backing of the board and auditor at the annual meeting.

If you are reassessing software exposure after Veeva Systems’ pullback, it could be a useful moment to look at other healthcare focused platforms through our screener of 40 healthcare AI stocks

With Veeva Systems now trading materially below some estimated fair value metrics and recent weakness driven mainly by macro headlines, is this pullback pointing to a mispriced healthcare software leader, or is the market already factoring in its future growth?

Most Popular Narrative: 38% Undervalued

With Veeva Systems closing at about $153.30 versus a narrative fair value near $245.48, the gap reflects a detailed set of growth and margin assumptions backed into that model.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

Want to see what kind of revenue ramp, margin profile, and future earnings multiple this narrative is baking in for Veeva Systems? The full framework sets out a defined growth path, an uplift in profitability, and a higher future P/E assumption tied directly to how much of the healthcare software stack Veeva could capture over time.

Result: Fair Value of $245.48 (UNDERVALUED)

However, Veeva Systems still faces real pressure from heavyweight CRM competitors and the risk that AI products fail to gain traction quickly enough to justify current assumptions.

Another View on Veeva Systems’ Valuation

While the narrative framework points to Veeva Systems trading at a large discount to a fair value of $245.48, the current P/E of 26.4x sits only slightly above the global Healthcare Services average of 26.2x and just below a fair ratio of 27.3x. This implies limited room for error if growth expectations soften.

Given that mix of signals, is the story here closer to a mispricing or a market that already prices in a fair share of execution risk?

Next Steps

Given the mixed signals around Veeva Systems, do you see cautious sentiment or an opportunity taking shape, and are you ready to weigh the upside for yourself? To size up what optimists are focusing on, start with the 3 key rewards.

Looking for more investment ideas beyond Veeva Systems?

If Veeva Systems has you rethinking your watchlist, this is the moment to broaden your view and line up your next set of stock ideas with focus.

Spot fresh opportunities and avoid tunnel vision by comparing different types of stocks side by side using the Simply Wall Street Screener.

• Target potential value plays by checking out companies flagged in the 45 high quality undervalued stocks to see where prices sit below key fundamentals.
• Prioritize staying power and resilience by reviewing stocks in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with disciplined fundamentals.
• Uncover less crowded opportunities by scanning the screener containing 19 high quality undiscovered gems that may not yet be on most investors’ radar but pass strict quality filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.